IL225443A0 - A combined crystal of aprefitant and l-proline, preparations containing it and its uses - Google Patents
A combined crystal of aprefitant and l-proline, preparations containing it and its usesInfo
- Publication number
- IL225443A0 IL225443A0 IL225443A IL22544313A IL225443A0 IL 225443 A0 IL225443 A0 IL 225443A0 IL 225443 A IL225443 A IL 225443A IL 22544313 A IL22544313 A IL 22544313A IL 225443 A0 IL225443 A0 IL 225443A0
- Authority
- IL
- Israel
- Prior art keywords
- aprepitant
- compositions
- same
- proline cocrystal
- cocrystal
- Prior art date
Links
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 title 1
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 title 1
- 229960001372 aprepitant Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38574410P | 2010-09-23 | 2010-09-23 | |
| US201161439654P | 2011-02-04 | 2011-02-04 | |
| US201161498214P | 2011-06-17 | 2011-06-17 | |
| PCT/IB2011/054210 WO2012038937A1 (en) | 2010-09-23 | 2011-09-23 | Aprepitant l-proline composition and cocrystal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL225443A0 true IL225443A0 (en) | 2013-06-27 |
Family
ID=44907915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL225443A IL225443A0 (en) | 2010-09-23 | 2013-03-21 | A combined crystal of aprefitant and l-proline, preparations containing it and its uses |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9029369B2 (OSRAM) |
| EP (1) | EP2618828B1 (OSRAM) |
| JP (1) | JP5997162B2 (OSRAM) |
| KR (1) | KR101833578B1 (OSRAM) |
| CN (1) | CN103221049B (OSRAM) |
| AR (1) | AR083095A1 (OSRAM) |
| AU (1) | AU2011306391B2 (OSRAM) |
| BR (1) | BR112013006651A2 (OSRAM) |
| CA (1) | CA2846460C (OSRAM) |
| ES (1) | ES2616752T3 (OSRAM) |
| IL (1) | IL225443A0 (OSRAM) |
| TW (1) | TWI540131B (OSRAM) |
| WO (1) | WO2012038937A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011306391B2 (en) | 2010-09-23 | 2016-12-15 | Nuformix Limited | Aprepitant L-proline composition and cocrystal |
| CN104159584A (zh) * | 2011-11-25 | 2014-11-19 | 诺弗米克斯有限公司 | 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体 |
| US10098859B2 (en) | 2012-09-05 | 2018-10-16 | Amri Ssci, Llc | Cocrystals of p-coumaric acid |
| WO2015101596A2 (en) * | 2013-12-30 | 2015-07-09 | Oncoprevent Gmbh | Neurokinin-1 receptor antagonists for use in a method of prevention of cancer |
| JP2021512910A (ja) | 2018-02-07 | 2021-05-20 | リアタ ファーマシューティカルズ インコーポレイテッド | ノボビオシン類似体とプロリンとの共結晶形態 |
| CN116283947A (zh) * | 2023-02-07 | 2023-06-23 | 成都医学院 | 一种阿瑞匹坦共晶及其制备方法和用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US6048859A (en) | 1992-06-29 | 2000-04-11 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
| US5719147A (en) | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
| IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| ZA985765B (en) | 1997-07-02 | 1999-08-04 | Merck & Co Inc | Polymorphic form of a tachykinin receptor antagonist. |
| US20050025791A1 (en) * | 2002-06-21 | 2005-02-03 | Julius Remenar | Pharmaceutical compositions with improved dissolution |
| EP1608339B8 (en) * | 2003-02-28 | 2012-04-25 | McNeill-PPC, Inc. | Pharmaceutical co-crystal of celecoxib-nicotinamide |
| US20090209541A1 (en) * | 2006-06-16 | 2009-08-20 | Dr. Reddy's Laboratories Ltd. | Aprepitant compositions |
| US20110009362A1 (en) * | 2008-02-27 | 2011-01-13 | Dr. Reddy's Laboratories Ltd. | Solubility-enhanced forms of aprepitant and pharmaceutical compositions thereof |
| AU2011306391B2 (en) | 2010-09-23 | 2016-12-15 | Nuformix Limited | Aprepitant L-proline composition and cocrystal |
-
2011
- 2011-09-23 AU AU2011306391A patent/AU2011306391B2/en active Active
- 2011-09-23 CN CN201180055997.5A patent/CN103221049B/zh active Active
- 2011-09-23 ES ES11779217.6T patent/ES2616752T3/es active Active
- 2011-09-23 US US13/825,380 patent/US9029369B2/en active Active
- 2011-09-23 AR ARP110103486 patent/AR083095A1/es unknown
- 2011-09-23 BR BR112013006651A patent/BR112013006651A2/pt not_active Application Discontinuation
- 2011-09-23 CA CA2846460A patent/CA2846460C/en active Active
- 2011-09-23 JP JP2013529758A patent/JP5997162B2/ja active Active
- 2011-09-23 WO PCT/IB2011/054210 patent/WO2012038937A1/en not_active Ceased
- 2011-09-23 KR KR1020137010228A patent/KR101833578B1/ko active Active
- 2011-09-23 TW TW100134362A patent/TWI540131B/zh active
- 2011-09-23 EP EP11779217.6A patent/EP2618828B1/en active Active
-
2013
- 2013-03-21 IL IL225443A patent/IL225443A0/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US20130252949A1 (en) | 2013-09-26 |
| EP2618828B1 (en) | 2016-11-23 |
| AU2011306391A1 (en) | 2013-04-11 |
| HK1187554A1 (zh) | 2014-04-11 |
| EP2618828A1 (en) | 2013-07-31 |
| CN103221049A (zh) | 2013-07-24 |
| TW201217366A (en) | 2012-05-01 |
| JP5997162B2 (ja) | 2016-09-28 |
| KR20140040671A (ko) | 2014-04-03 |
| US9029369B2 (en) | 2015-05-12 |
| CN103221049B (zh) | 2015-11-25 |
| AR083095A1 (es) | 2013-01-30 |
| AU2011306391B2 (en) | 2016-12-15 |
| BR112013006651A2 (pt) | 2017-07-18 |
| CA2846460C (en) | 2019-01-08 |
| TWI540131B (zh) | 2016-07-01 |
| WO2012038937A1 (en) | 2012-03-29 |
| ES2616752T3 (es) | 2017-06-14 |
| JP2013537901A (ja) | 2013-10-07 |
| KR101833578B1 (ko) | 2018-02-28 |
| CA2846460A1 (en) | 2012-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269858A (en) | Pyridone and aza-pyridone compounds, pharmaceutical composition and kits comprising the same and uses thereof | |
| IL221210A0 (en) | Heterocyclic compounds, compositions comprising the same and uses thereof | |
| IL233154A (en) | Compounds, pharmaceuticals containing them and their uses | |
| IL225926A0 (en) | Boronate compounds, preparations containing them and their uses | |
| IL227815B (en) | Pyrrolopyrazine-spirocyclic piperidine amide compounds, and preparations containing them and their uses | |
| IL228715A0 (en) | Aminopyrazine compounds, preparations containing them and their uses | |
| IL222484A0 (en) | Arginase inhibitor compounds, compositions comprising the same and uses thereof | |
| IL216254A (en) | Compounds, pharmaceutical compositions and their uses | |
| IL220283A0 (en) | 4-oxo-ih-quinoline-3- carboxamides, compositions comprising the same and uses thereof | |
| IL228322A0 (en) | History of dispiropyrrolidine, preparations containing them and their uses | |
| IL227963A0 (en) | History History of cytotoxic benzodiazepines, preparations containing them and their uses | |
| AP2012006314A0 (en) | Antiparistic dihydroazole compounds and compositions comprising same. | |
| PL2588556T3 (pl) | Kompozycja na bazie 2,3,3,3-tetrafluoropropenu | |
| IL220009A0 (en) | Indole compounds, compositions comprising the same and uses thereof | |
| IL226383B (en) | Antibodies against ccl20, preparations containing them and their uses | |
| PT2431442T (pt) | Composição à base de 1,3,3,3-tetrafluoropropeno | |
| IL224288A (en) | Derivatives of converted pyrazolamide, pharmaceutical preparations containing them and their use | |
| IL226023A0 (en) | Antibodies against 5dr, preparations containing them and their uses | |
| IL221209A0 (en) | Pyrazolo piperidine derivatives, compositions comprising the same and uses thereof | |
| IL221207A0 (en) | Pyrazolo piperidine derivatives, compositions comprising the same and uses thereof | |
| IL221906B (en) | pde10 suppressor compounds, preparations containing them and their uses | |
| IL223405B (en) | Phosphoplatins, preparations containing them and their uses | |
| EP2599490A4 (en) | COMPOSITION FOR TREATMENT OF INJURY, FORMULATION AND USE THEREOF | |
| PL2619278T3 (pl) | Kompozycja na bazie 3,3,3-trifluoropropenu | |
| PL2646520T3 (pl) | Kompozycja na bazie 1,1,1,4,4,4-heksafluorobut-2-enu i 3,3,4,4,4-pentafluorobut-1-enu |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |